Thrombin activatable fibrinolysis inhibitor (TAFI)—How does thrombin regulate fibrinolysis?
- 1 January 2006
- journal article
- review article
- Published by Taylor & Francis in Annals of Medicine
- Vol. 38 (6) , 378-388
- https://doi.org/10.1080/07853890600852898
Abstract
The thrombin‐catalysed conversion of plasma fibrinogen into fibrin and the development of an insoluble fibrin clot are the final steps of the coagulation cascade during haemostasis. A delicate balance between coagulation and fibrinolysis determines the stability of the fibrin clot. Thrombin plays a central role in this process, it not only forms the clot but it is also involved in stabilizing the clot by activating thrombin activatable fibrinolysis inhibitor (TAFI). Activated TAFI protects the fibrin clot against lysis. Here we will discuss the mechanisms for regulation of fibrinolysis by thrombin. The role of the coagulation system for the generation of thrombin and for the activation of TAFI implies that defects in thrombin generation will directly affect the protection of clots against lysis. Thus, defects in activation of TAFI might contribute to the severity of bleeding disorders. Vice versa an increased activation of TAFI due to an increased rate of thrombin generation might lead to thrombotic disorders. Specific inhibitors of activated TAFI or inhibitors that interfere with the generation of thrombin might provide novel therapeutic strategies for thrombolytic therapy. Besides having a role in the regulation of fibrinolysis, TAFI may also have an important function in the regulation of inflammation, wound healing and blood pressure.Keywords
This publication has 89 references indexed in Scilit:
- Combined carrier status of prothrombin 20210A and factor XIII-A Leu34 alleles as a strong risk factor for myocardial infarction: evidence of a gene-gene interactionBlood, 2003
- Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic riskBlood, 2003
- Thrombin-Activatable Fibrinolysis Inhibitor (TAFI, Plasma Procarboxypeptidase B, Procarboxypeptidase R, Procarboxypeptidase U)Thrombosis Research, 2001
- Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophiliaBlood, 2000
- Sol Sherry Lecture in ThrombosisArteriosclerosis, Thrombosis, and Vascular Biology, 2000
- Factor XI and Protection of the Fibrin Clot against Lysis – a Role for the Intrinsic Pathway of Coagulation in FibrinolysisThrombosis and Haemostasis, 1998
- Purification and Characterization of TAFI, a Thrombin-activable Fibrinolysis InhibitorJournal of Biological Chemistry, 1995
- Dusart syndrome: a new concept of the relationship between fibrin clot architecture and fibrin clot degradability: hypofibrinolysis related to an abnormal clot structureBlood, 1993
- An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunitsBiochemical and Biophysical Research Communications, 1989
- Significance of Cross-Linking of α2-Plasmin Inhibitor to Fibrin in Inhibition of Fibrinolysis and in HemostasisJournal of Clinical Investigation, 1982